Ceporex Vet Oral Drops Data Sheet
Presentation
Ceporex Vet Oral Drops are presented as pale orange granules with a characteristic odour for reconstitution with water to give a sweetened orange-coloured suspension (syrup) containing 100 mg/ml cefalexin.
Uses
As a broad spectrum antibiotic with bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, for use in cats and small dogs.
The product is effective against the following micro-organisms in vitro: Staphylococcus spp (including penicillin-resistant strains), Streptococcus spp, Corynebacterium spp, Pasteurella multocida, Escherichia coli, Micrococcus spp, Moraxella spp.
When susceptible organisms are present, Ceporex Vet Oral Drops may be effective in the treatment of infection of the respiratory tract, urogenital tract, the skin and localised infections, in soft tissue.
In dogs it may also be effective in the treatment of infections of the gastrointestinal tract.
Dosage and administration
Ceporex Vet Oral Drops are prepared by adding 6 ml of drinking water to the granules and mixing thoroughly before each withdrawal from the bottle. Administer directly into the mouth or added to food.
The recommended dose rate is 10 to 15 mg/kg bodyweight (equivalent to 1.0 to 1.5 ml Ceporex Vet Oral Drops per 10 kg bodyweight) twice daily.
Treatment for five days is recommended.
The following is intended as a guide:
Dogs
11 kg to 20 kg bodyweight: 1 to 3 ml drops twice daily.
6 kg to 10 kg bodyweight: 0.5 to 1.5 ml drops twice daily.
5 kg and less bodyweight: 0.5 to 1.0 ml drops twice daily.
Cats
Average dose rate: 0.5 ml drops twice daily.
Any variation should be at the discretion of the prescribing veterinary surgeon, e.g. in cases where the condition requires an extended course of treatment (such as chronic pyoderma).
Contra-indications, warnings, etc
Contra-indications
Do not administer to animals which are known to be hypersensitive to cefalexin. In cases of known renal insufficiency, the dose of the product should be reduced.
Operator warnings
Cephalosporins may cause sensitisation (allergy) following injection, inhalation, ingestion or skin contact. Sensitivity to penicillin may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.
- Do not handle this product (or these products) if you know you are sensitised, or if you have been advised not to work with such preparations.
- Handle this product with great care to avoid exposure, taking all recommended precautions.
- If you develop symptoms following exposure such as a skin rash you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
Wash hands after use of this product.
For animal treatment only.
Keep out of the reach of children.
Pharmaceutical precautions
Protect from light. Do not store above 25°C.
When reconstituted, do not store above 25°C and preferably in a refrigerator; any reconstituted product remaining ten days after preparation should be discarded.
Shake the bottle before withdrawing each dose.
Disposal
Dispose of empty packaging and any remaining product in the household refuse.
Legal category
POM-V - To be supplied only on veterinary prescription
Packaging Quantities
Bottles of granules for oral suspension to make up 10 ml. A graduated plastic dropper is supplied with each pack.
Further information
Cefalexin is rapidly, and almost completely, absorbed after oral administration. Effective blood levels are generally achieved within two hours of dosing. Cefalexin is excreted in the urine in high concentration.
Cefalexin is resistant to the action of staphylococcal penicillinase and is therefore active against the strains of Staphylococcus aureus that are insensitive to penicillin (or related antibiotics such as ampicillin or amoxycillin) because of production of penicillinase. Cefalexin is also active against the majority of ampicillin-resistant E. coli.
The administration of cefalexin has been shown to produce no serious side-effects at many times the recommended dose rate.
Marketing authorisation number
Vm 00201/4076.
